 |
|
Single Daily Dose Treatment of Severe Refractory Infections With CeftriaxoneCost Savings and Possible Parenteral Outpatient Treatment
Jean-Daniel Baumgartner, MD;
Michel P. Glauser, MD
Arch Intern Med. 1983;143(10):1868-1873.
Abstract
• Ceftriaxone sodium, a new cephalosporin with a very broad spectrum of action and a very long serum half-life, was administered to 127 patients in the treatment of 133 severe infections at our institution in Lausanne, Switzerland. Eighty infections had previously been treated unsuccessfully with other antimicrobials to which the pathogens were most often resistant. Sixty-five episodes were treated with two daily injections until there was an improvement in the patient's clinical condition, while 67 infections were treated from the start by a single daily injection. The results in the two groups were similar. One hundred fifteen infections (86%) were cured or improved, ten (8%) did not respond to therapy or recurred, and eight (6%) were not evaluable. The treatment was well tolerated, even by the 18 patients who received the drug for more than four weeks. The administration of a single daily dose instead of four doses as with standard antibiotic regimens produced a saving of Sfr 84,000 ($42,000) in the 127 patients. The single daily dose also made it possible to treat 25 of the 127 severely ill patients as outpatients, with a saving of Sfr 388,500 ($195,000) with respect to the hospital costs that would have been incurred for the same time period.
(Arch Intern Med 1983;143:1868-1873)
Author Affiliations
From the Division des Maladies Infectieuses, Départment de Médecine Interne, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Footnotes
Accepted for publication May 19, 1983.
Reprint requests Division des Maladies Infectieuses, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland (Dr Glauser).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Practice Guidelines for Outpatient Parenteral Antimicrobial Therapy
Tice et al.
Clinical Infectious Diseases 2004;38:1651-1671.
FULL TEXT
|
